There are currently 997 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/17/2025
Locations: University of South Florida, Tampa, Florida
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
NCT06643377
Recruiting
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic (PK) study). Researchers will compare what happens to enlicitide in the body when it is given to people with severe renal impairment (mea... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/17/2025
Locations: Genesis Clinical Research, LLC ( Site 0001), Tampa, Florida
Conditions: Healthy, Renal Impairment
Register for Updates
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498
Recruiting
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded ind... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329
Recruiting
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Urothelial Carcinoma
Register for Updates
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: R & B Medical Center, Tampa, Florida
Conditions: Severe Hypertriglyceridemia
Register for Updates
A Study of Obexelimab in Patients with Systemic Lupus Erythematosus
NCT06559163
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: Clinical Research of West Florida, Inc., Tampa, Florida
Conditions: Systemic Lupus Erythematosus
Register for Updates
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
NCT05651828
Recruiting
The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Advanced Basal Cell Carcinoma
Register for Updates
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
NCT06497569
Recruiting
The purpose of this study is to determine how the STRONG intervention compares with usual care for reducing malnutrition among gastroesophageal cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: GastroEsophageal Cancer
Register for Updates
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
NCT06660368
Recruiting
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Register for Updates
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251
Recruiting
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/14/2025
Locations: Retina Associates of Florida, LLC, Tampa, Florida
Conditions: Neovascular Age-Related Macular Degeneration
Register for Updates
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
NCT04365374
Recruiting
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital, Tampa, Florida
Conditions: Brain Metastases
Register for Updates
Pancreatic Cancer Early Detection Consortium
NCT04970056
Recruiting
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/14/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Register for Updates